ARRA RECOVERY ACT - TISSUE SOURCE SITE (TSS) IN SUP

TCGA历来依赖于回顾性收集的生物标本。这些组织是由世界各地的数十家tss通过主承包商SAIC-Frederick管理的一系列分包合同积累的。tss包括临床站点、学术机构以及拥有生物储存库的商业公司。回顾性样本是组织和临床数据的宝贵来源，通常包括长期随访。然而，严格的生物标本质量，包括所需的组织量（在100-150mg之间），肿瘤核的百分比（至少70%）和低坏死量（小于30%），提出了挑战，要求TCGA也要考虑未来的收集。该项目的目的是建立组织源站点（TSS）网络，能够通过回顾性和前瞻性收集提供临床注释的生物标本。组织和临床数据将被送到TCGA的生物标本核心资源（BCR）进行储存、质量控制、加工成分子分析物和其他研究工作。最终，将对样品进行拷贝数变异、单核苷酸多态性、表观基因组谱、基因和miRNA表达和突变分析。

TCGA has historically relied on retrospectively collected biospecimens. These tissues were accrued by dozens of TSSs around the world through a series of subcontracts managed through the prime contractor at SAIC-Frederick. TSSs included clinical sites, academic institutions as well as commercial companies with biorepositories. Retrospective samples have been invaluable sources of tissue and clinical data, often including long term follow-up. However, the rigorous biospecimen quality, including amount of tissue needed (between 100-150mg), percent of tumor nuclei (at least 70%) and low amount of necrosis (less than 30%) has posed challenges, requiring TCGA to look also at prospective collections. The purpose of this project is to establish Tissue Source Site (TSS) networks capable of delivering clinically annotated biospecimens through either/both retrospective and prospective collections. The tissues and clinical data will be delivered to one of TCGA¿s Biospecimen Core Resource(s) (BCR) for storage, quality control, processing into molecular analytes, and other research efforts. Ultimately, the samples will be characterized for copy number variation, single nucleotide polymorphisms, epigenomic profiles, gene and miRNA expression and mutation analysis.